Plethora Solutions Holdings Plc Regulatory News (PLE)

Plethora Solutions Holdings plc

("Plethora" or the "Company")

Result of General Meeting

Plethora Solutions Holdings plc (AIM: PLE), the UK-based speciality pharmaceutical company, announces that all resolutions were duly passed at the General Meeting of the Company held earlier today.

The remaining conditions in relation to the placing have been satisfied. The placing (the "Placing") of 48,085,000 new ordinary shares of 1 penny each (the "New Ordinary Shares"), at a price of 2.5 pence per share (the "Placing Shares"), is now unconditional save for admission of the Placing Shares to AIM ("Admission"). In addition, £1.655 million (plus accrued interest of £518,668) of £2.455 million outstanding convertible loan notes have been converted into new ordinary shares through the issue of 86,946,731 New Ordinary Shares (the "Conversion Shares") to certain convertible loan noteholders.

The Placing Shares and Conversion Shares will, on Admission, be credited as fully paid and will have the same rights in all respects with the existing ordinary shares, including the right to receive all dividends and other distributions declared.

It is expected that Admission will be effective and trading will commence at 8:00 am on 18 October 2011. Following Admission, the Company will have 200,757,531 Ordinary Shares in issue. Since the Company holds no shares in Treasury, the total number of voting rights in the Company is therefore 200,757,531 and this figure may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

Enquiries:

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company is focused on: (i) driving the development of its specialty sales and marketing business, The Urology Company; and (ii) seeking to increase the value of its development assetsthe most advanced of which is PSD502 for the treatment of premature ejaculation.

Plethora's subsidiary, The Urology Company Limited, established in 2009, markets and distributes a range of branded and generic pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, andrology and obstetric conditions. Its products fall into to categories (i) Professional - where a physician, nurse or other healthcare professional makes a prescribing decision and include Striant®SR, Urolieve®, Hyalofemme®and Dianatal®; and (ii) Consumer - where the consumer/patient makes a buying decision and include Hyalofemme®, Multi-Gyn®, Multi-Mam®and hI-Cran®.

The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.ukand www.theurologyco.com